Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.
Saved in:
| Title: | Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024. |
|---|---|
| Authors: | Zhou S; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Lei L; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Jiang L; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Fu C; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Huang J; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Zhang K; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Wen Y; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Chen J; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Zeng Q; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China. |
| Source: | Expert opinion on drug safety [Expert Opin Drug Saf] 2026 May; Vol. 25 (5), pp. 981-986. Date of Electronic Publication: 2024 Dec 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2024.2446432 |
